Introduction and purpose Agricultural biotechnology is one of the most promising and controversial industries of the 20th and 21st centuries. Firms involved in agricultural biotechnology (henceforth referred to as`agro-bio') typically used advanced biotechnology methods to genetically modify plant life in order to achieve particular plant characteristics, lower costs, and to increase crop yields (for example, herbicide tolerance, pesticide resistance, virus resistance, and increased nutritional value). The primary consumers of agriculturally derived products are farmers; the secondary consumers are the food industry, retailers, and the public. Opponents often cite two general arguments against the use of genetically modified organisms (GMOs): the potential harm to human life; and the possible ill effects they can cause to the environment (McGarity and Hansen, 2001; Marris et al, 2001; United Nations, 2001). The potential harms to the environment and public welfare include threatened or weakened ecosystems, the reduction of biodiversity by harming existing species, the creation of gene flow (the process of transferring novel genes to nontargeted plants), the creation of`superweeds', and increased resistance to pesticides in pests and, hence, the inability to use traditional pesticides. The purpose of this paper is threefold: to examine the characteristics of US agrobio firms, especially the small and medium-sized (SMEs); to understand firm-specific strategies utilized to remain competitive in an uncertain business and regulatory environment; and to examine the importance of two external factors, governments and farmers, in innovation and commericialization of agro-bio products. More specifically, the influence of policy on firm-level strategy is examined. The analysis presented in this